• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

10 Minutes Supine Is Sufficient for Intratympanic Dexamethasone Injection

by Amy Eckner • December 9, 2014

  • Tweet
  • Email
Print-Friendly Version

How long should patients remain in the supine treatment position after intratympanic dexamethasone injection (ITDI)?

Background: ITDI provides the potential for direct delivery of high concentration steroid to the inner ear while avoiding systemic effects. Many studies have shown that ITDI is an effective treatment in patients with sudden hearing loss, especially in those with refractory hearing loss. Although many clinicians use ITDI for sudden hearing loss, the detailed injection protocol varies according to the provider, with treatment times ranging from 15 to 40 minutes.

You Might Also Like

  • Intratympanic Dexamethasone Injection as Effective as Alternative Treatments for SSNHL
  • ITSI Effective for Some Cases of Idiopathic Tinnitus
  • IT Steroid Treatment, Oral Corticosteroid Therapy Similar for Sudden Sensorineural Hearing Loss
  • Intratympanic Drug Therapy Effective for Ménière’s Disease
Explore This Issue
December 2014

Study design: Prospective study.

Setting: Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea

Synopsis: Through an in vivo animal study, the researchers used 24 six-week-old male mice randomized into six groups of four mice each, according to treatment wait time after intratympanic injection: 5, 10, 15, 20, 25, and 30 minutes post injection. The dexamethasone solution was created with dexamethasone 21-phosphate disocium salt and 0.9% NaCl. All mice received 10 µL of solution. The perilymph was sampled through the round window. The concetration of dexamethasone in the samples was analyzed immediately, along with the concentration of verapamil.

In a separate prospective clinical study, 79 patients with refractory sudden hearing loss underwent intratympanic injection, and remained in the supine position with their heads rotated 45 degrees to the unaffected side. Patients were divided into two groups based on wait time postinjection: 30 minutes and 10 minutes.

In the in vivo study, the concentration of dexamethasone showed no significant increase after 10 minutes, and in the clinical study, hearing improvement was similar for both the 30-minute and the 10-minute groups.

Bottom line: Ten minutes is a sufficient time to remain in the supine treatment position after ITDI in patients with sudden hearing loss.

Citation: Park SH, Park C, Seo J, Cho JH, Moon IS. How long should patients remain in the supine treatment position after intratympanic dexamethasone injection? Laryngoscope. 2014;124:2807-2810.

Filed Under: Literature Reviews, Otology/Neurotology, Otology/Neurotology, Practice Focus Tagged With: intratympanic drug therapyIssue: December 2014

You Might Also Like:

  • Intratympanic Dexamethasone Injection as Effective as Alternative Treatments for SSNHL
  • ITSI Effective for Some Cases of Idiopathic Tinnitus
  • IT Steroid Treatment, Oral Corticosteroid Therapy Similar for Sudden Sensorineural Hearing Loss
  • Intratympanic Drug Therapy Effective for Ménière’s Disease

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Have you invented or patented something that betters the field of otolaryngology?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • The Best Site for Pediatric TT Placement: OR or Office?

    • The Road Less Traveled—at Least by Otolaryngologists

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Leaky Pipes—Time to Focus on Our Foundations
    • You Are Among Friends: The Value Of Being In A Group
    • How To: Full Endoscopic Procedures of Total Parotidectomy
    • How To: Does Intralesional Steroid Injection Effectively Mitigate Vocal Fold Scarring in a Rabbit Model?
    • What Is the Optimal Anticoagulation in HGNS Surgery in Patients with High-Risk Cardiac Comorbidities?

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939